CD274 and neoplasm: They can block PD-1/PD-L1 interaction, activate T cells, and restore their anti-tumor immune response.[3] Tislelizumab[4,5] is a humanized monoclonal antibody against PD-1(IgG4 variant) that was independently developed in China.